美國居民不適用 XM 服務。
R
R

Regeneron

交易方向

交易者脈動

技術摘要

小時

財經新聞

Prices for new US drugs rose 35% in 2023, more than the previous year

ANALYSIS-Prices for new US drugs rose 35% in 2023, more than the previous year By Deena Beasley Feb 23 (Reuters) - Pharmaceutical companies last year launched new U.S. drugs at prices 35% higher than in 2022, reflecting in part the industry's embrace of expensive therapies for rare diseases like muscular dystrophy, a Reuters analysis found. The median annual list price for a new drug was $300,000 in 2023, according to the Reuters analysis of 47 medicines, up from $222,000 a year earlier .
P
R
V

Linvoseltamab BLA For Treatment Of Relapsed/Refractory Multiple Myeloma Accepted For FDA Priority Review

BRIEF-Linvoseltamab BLA For Treatment Of Relapsed/Refractory Multiple Myeloma Accepted For FDA Priority Review Feb 21 (Reuters) - Regeneron Pharmaceuticals Inc REGN.O : LINVOSELTAMAB BLA FOR TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA ACCEPTED FOR FDA PRIORITY REVIEW REGENERON PHARMACEUTICALS INC: TARGET ACTION DATE FOR FDA DECISION IS AUGUST
R

FDA puts on hold two drug trials of Rapt Therapeutics in 'major setback'

UPDATE 3-FDA puts on hold two drug trials of Rapt Therapeutics in 'major setback' Adds CEO comments in paragraph 4 and 5, updates shares in paragraph 2 By Puyaan Singh Feb 20 (Reuters) - Rapt Therapeutics RAPT.O said on Tuesday the U.S. FDA had placed on hold two mid-stage trials of the company's drug to treat eczema and asthma, after liver failure was observed in one of the patients.
R
S

Sandoz slips after MS cuts on risks for US biosimilars

BUZZ-Sandoz slips after MS cuts on risks for US biosimilars ** Shares in Sandoz SDZ.S slide around 4% after Morgan Stanley cut the Swiss drug maker to "equal weight " from "overweight", citing risks to biosimilars in the U.S. ** MS says it sees risks to Sandoz's U.S. biosimilar launch timelines due to IP litigation between biosimilar makers and originators, as exemplified by recent Regeneron REGN.O win against Viatris VTRS.O on eye drug Eylea ** While one of Sandoz's expected launches has been c
N
R

Regeneron Pharmaceuticals Says Japan Approves Dupixent For Chronic Spontaneous Urticaria

BRIEF-Regeneron Pharmaceuticals Says Japan Approves Dupixent For Chronic Spontaneous Urticaria Feb 16 (Reuters) - Regeneron Pharmaceuticals Inc REGN.O : JAPAN FIRST IN WORLD TO APPROVE DUPIXENT® (DUPILUMAB) FOR CHRONIC SPONTANEOUS URTICARIA (CSU) APPROVAL BASED ON RESULTS FROM PHASE 3 TRIAL SHOWING DUPIXENT SIGNIFICANTLY REDUCED ITCH COMPARED TO P
R

細節

熱門資產

免責聲明: XM Group提供線上交易平台的登入和執行服務,允許個人查看和/或使用網站所提供的內容,但不進行任何更改或擴展其服務和訪問權限,並受以下條款與條例約束:(i)條款與條例;(ii)風險提示;(iii)完全免責聲明。網站內部所提供的所有資訊,僅限於一般資訊用途。請注意,我們所有的線上交易平台內容並不構成,也不被視為進入金融市場交易的邀約或邀請 。金融市場交易會對您的投資帶來重大風險。

所有缐上交易平台所發佈的資料,僅適用於教育/資訊類用途,不包含也不應被視爲適用於金融、投資稅或交易相關諮詢和建議,或是交易價格紀錄,或是任何金融商品或非應邀途徑的金融相關優惠的交易邀約或邀請。

本網站的所有XM和第三方所提供的内容,包括意見、新聞、研究、分析、價格其他資訊和第三方網站鏈接,皆爲‘按原狀’,並作爲一般市場評論所提供,而非投資建議。請理解和接受,所有被歸類為投資研究範圍的相關内容,並非爲了促進投資研究獨立性,而根據法律要求所編寫,而是被視爲符合營銷傳播相關法律與法規所編寫的内容。請確保您已詳讀並完全理解我們的非獨立投資研究提示和風險提示資訊,相關詳情請點擊 這裡查看。

風險提示:您的資金存在風險。槓桿商品並不適合所有客戶。請詳細閱讀我們的風險聲明